Hims & Hers surges 4% as peptide policy shift unlocks growth
Shares of Hims & Hers Health moved sharply higher on Thursday, extending gains from the previous session after a significant regulatory shift signaled new opportunities in the peptide market. The stock rose about 4% to $25.28 on Thursday morning after closing up 14% on Wednesday, as investors reacted to comments from Robert F.
Hims & Hers Stock Stays Hot Amid Peptides Buzz
Hims & Hers Health Inc (NYSE:HIMS) is one of the best performing stocks on the New York Stock Exchange (NYSE) today, up 4.5% to trade at $25.52.
FDA Peptide Review, A Big Moment For Hims & Hers (Rating Upgrade)
Hims & Hers faces a pivotal regulatory moment as the FDA reconsiders compounded peptide therapies, especially GLP-1 drugs like semaglutide. A permissive FDA framework could legitimize compounded peptides, unlocking renewed growth and reversing the current revenue multiple discount for HIMS. Conversely, stricter FDA action could eliminate a key growth driver, reinforcing HIMS' high-beta exposure to regulatory risk.
Hims & Hers stock jumps as U.S. moves forward with plan to reassess popular peptides
Hims & Hers Health's plan to enter the business of selling peptides is looking a lot more realistic.
Hims & Hers Powers Patient-Provider Connectivity via Digital Platforms
HIMS unites telehealth, records and pharmacy fulfillment on one digital platform, adding AI tools, diagnostics and FDA-approved medicines.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $19.5, denoting a -4.08% move from the preceding trading day.
Hims & Hers Advances a Consumer-Centric Digital Health Platform
HIMS is broadening its digital-first platform with Labs, hormone therapy and weight-loss programs as it scales personalized care globally.
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Telehealth giant Hims & Hers says its customer support system was hacked
Hims & Hers, the telehealth company that sells weight-loss drugs and sexual health prescriptions, has confirmed a data breach affecting its third-party customer service platform.
Hims & Hers Expands Personalized Digital Healthcare Platform
HIMS builds a digital-first healthcare platform, integrating telehealth, AI and personalized treatments while expanding globally and into new specialties.
Hims & Hers Health, Inc. (HIMS) Registers a Bigger Fall Than the Market: Important Facts to Note
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $18.78, denoting a -3.1% move from the preceding trading day.
